Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | CNR1 | P21554 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324697 | 0.94 | CNR2 (0.54) | CNR2CNR1KMT2ADRD4SIGMAR1 | |
| SCHEMBL4326244 | 0.93 | CNR2 (0.60) | CNR2CNR1CYP1A2CASP1KMT2A | |
| SCHEMBL4320289 | 0.89 | CNR1 (0.49) | CNR2CNR1CYP1A2KMT2ADRD4 | |
| SCHEMBL4324702 | 0.87 | CNR2 (0.64) | CNR2CNR1CYP1A2KMT2ADRD4 | |
| SCHEMBL4325964 | 0.86 | CNR2 (0.52) | CNR2CNR1KMT2AHTR4 | |
| SCHEMBL4325256 | 0.85 | CNR1 (0.56) | CNR2CNR1LMNA | |
| SCHEMBL4327319 | 0.84 | CNR2 (0.54) | CNR2CNR1HTR3EHTR3BHTR1A | |
| SCHEMBL4334584 | 0.84 | CNR2 (0.57) | CNR2CNR1CYP1A2KMT2AHTR3E | |
| SCHEMBL4334740 | 0.83 | CNR1 (0.65) | CNR2CNR1LMNA | |
| SCHEMBL4321804 | 0.82 | CNR1 (0.55) | CNR2CNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885CYP1A2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.